Evidence map›Paper›PMID 36950488›Full record

ArticleJournal of clinical and experimental hepatology

The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study.

Heidi S Ahmed, Nikitha Gangasani, Manju B Jayanna, Michelle T Long, Antonio Sanchez, Arvind R Murali

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Heidi S AhmedBoston University School of Medicine, Section of Gastroenterology, Boston, MA, USA.
Nikitha GangasaniBoston University School of Medicine, Department of Internal Medicine, Boston, MA, USA.
Manju B JayannaLankenau Medical Center and Lankenau Institute for Medical Research, Wynnewood, PA, USA.
Michelle T LongBoston University School of Medicine, Section of Gastroenterology, Boston, MA, USA.
Antonio SanchezThe University of Iowa Hospitals and Clinics, Department of Internal Medicine, Gastroenterology and Hepatology, Iowa City, IA, USA.
Arvind R MuraliThe University of Iowa Hospitals and Clinics, Department of Internal Medicine, Gastroenterology and Hepatology, Iowa City, IA, USA.
Boston University · USUniversity of Iowa Hospitals and Clinics · USLankenau Institute for Medical Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The NAFLD decompensation risk score (the Iowa Model) was recently developed to identify patients with nonalcoholic fatty liver disease (NAFLD) at highest risk of developing hepatic events using three variables-age, platelet count, and diabetes. Aims: We performed an external validation of the Iowa Model and compared it to existing non-invasive models. Methods: We included 249 patients with NAFLD at Boston Medical Center, Boston, Massachusetts, in the external validation cohort and 949 patients in the combined internal/external validation cohort. The primary outcome was the development of hepatic events (ascites, hepatic encephalopathy, esophageal or gastric varices, or hepatocellular carcinoma). We used Cox proportional hazards to analyze the ability of the Iowa Model to predict hepatic events in the external validation (https://uihc.org/non-alcoholic-fatty-liver-disease-decompensation-risk-score-calculator). We compared the performance of the Iowa Model to the AST-to-platelet ratio index (APRI), NAFLD fibrosis score (NFS), and the FIB-4 index in the combined cohort. Results: The Iowa Model significantly predicted the development of hepatic events with hazard ratio of 2.5 [95% confidence interval (CI) 1.7-3.9, Conclusions: In an urban, racially and ethnically diverse population, the Iowa Model performed well to identify NAFLD patients at higher risk for liver-related complications. The model provides the individual probability of developing hepatic events and identifies patients in need of early intervention.

Indexed as

A1AT, alpha-1-antitrypsinAASLD, the American Association for the Study of Liver DiseaseALD, alcoholic liver diseaseALT, alanine aminotransferaseAPRI, AST-to-Platelet Ratio IndexAST, aspartate aminotransferaseAUROC, area under the receiver operating characteristic curveBMI, body mass indexcirrhosisCT, computed tomographyfatty liverHCV, hepatitis C infectionHE, hepatic encephalopathyNAFLD, nonalcoholic fatty liver diseaseNASH, nonalcoholic steatohepatitisnonalcoholic fatty liver diseaserisk assessmentSAS, Statistical Analysis SoftwareVCTE, vibration-controlled transient elastography

Identifiers

PMID36950488
PMCPMC10025751
OpenAlexW4309047620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.